Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amplimexon in previously treated lymphoma
NCT01314014Phase 2Completed
- Sponsor
- University of Rochester
- Start
- May 2011
- Primary completion
- Mar 2013
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of imexon in follicular lymphoma (FL), small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), Lymphoplasmacytic Lymphoma (LPL), diffuse large B-cell lymphoma (DLBCL), sponsored by University of Rochester. Started May 2011; status: completed.
02
Drugs
imexon
03
Conditions
follicular lymphoma (FL)small lymphocytic lymphoma (SLL)marginal zone lymphoma (MZL)Lymphoplasmacytic Lymphoma (LPL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01314014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01314014.